by Jason Farmer | Jul 28, 2026 | Financial Oversight
The 2026 physician fee schedule widens the gap between office-based and facility-based payment for interventional pain procedures. Understanding the full economics – not just the facility rate – is the difference between a profitable procedure mix and a...
by Jason Farmer | Jul 26, 2026 | Operations
Prime Therapeutics found only about 1 in 12 patients who started a GLP-1 for obesity were still on therapy at three years. Every dollar you spend on acquisition runs through that number first. Key TakeawaysPrime Therapeutics reported that only 8 percent – about...
by Jason Farmer | Jul 24, 2026 | Compliance & Risk
DEA enforcement against pain practices intensified through 2025 and into 2026. The practices that survive scrutiny share one thing: a prescribing program that was documented, consistent, and already running before the auditor arrived. Key TakeawaysEvery state now...
by Jason Farmer | Jul 24, 2026 | Growth Strategy
PE consolidation in orthopedics has slowed from its 2019-2022 peak but has not stopped – 14 active U.S. platform MSOs were operating in mid-2026. The decision to sell is irreversible. The evaluation deserves more structure than most groups bring to it. Key...
by Jason Farmer | Jul 23, 2026 | Financial Oversight
Commercial contracts that have not been actively managed in three years are almost certainly paying below market. And starting in 2026, 741 hospitals are mandatory participants in a new bundled payment model that reaches directly into how orthopedic surgeons are paid....
